Internal Medicine · Garden Grove, CA
NPI
1437321932
Since 2008
Specialty
Internal Medicine
Code 207R00000X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
9191 Westminster Ave
Garden Grove, CA, 92844
Phone (714) 899-2000
Groups this clinician bills Medicare through
Medicare paid, 2024
$906K
15,802 services
Medicare patients, 2024
1,896
Average age 75
Drug cost, 2024
$10.5M
50,680 prescriptions
Company payments, 2025
$11K
From 54 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael M Dao was code 99490 (chronic, principal, and transitional care management), 5,125 times for 726 patients. In total Michael M Dao billed 15,802 services in 73 codes, and Medicare paid $906K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-03-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99490 Chronic, Principal, and Transitional Care Management | Office | 5,125 | 726 | $51.61 | $264K |
| 99213 Office E&M - Established | Office | 4,119 | 1,308 | $67.91 | $280K |
| 99214 Office E&M - Established | Office | 967 | 804 | $87.90 | $85K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 923 | 165 | $0.68 | $632 |
| 96372 Injection Administration | Office | 879 | 375 | $10.83 | $9,524 |
| 20610 Joint Injection | Office | 754 | 215 | $46.01 | $35K |
| J7324 Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | Office | 645 | 184 | $95.78 | $62K |
| G0008 Administration of influenza virus vaccine | Office | 572 | 570 | $35.02 | $20K |
| 90662 Vaccine Product | Office | 389 | 388 | $81.67 | $32K |
| 93000 Electrocardiogram | Office | 178 | 162 | $10.72 | $1,908 |
| 90653 Vaccine Product | Office | 166 | 166 | $81.82 | $14K |
| 99496 Chronic, Principal, and Transitional Care Management | Office | 137 | 115 | $239.66 | $33K |
| 87811 Immunoassay | Office | 95 | 86 | $40.55 | $3,852 |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 80 | 55 | $0.88 | $70.7 |
| 99203 Office E&M - New | Office | 73 | 73 | $72.16 | $5,267 |
By year: 2022 $1.2M for 16,373 services; 2023 $1.3M for 14,968 services; 2024 $906K for 15,802 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 87811 Immunoassay | 95 | 86 | $40.55 | $3,852 |
| 81002 Clinical Chemistry | 37 | 35 | $3.41 | $126 |
Medicare prescription drug claims, 2024
In 2024, the drug Michael M Dao prescribed most often to Medicare patients was Atorvastatin Calcium, with 2,477 prescriptions and refills. In total Michael M Dao wrote 50,680 Medicare prescriptions that cost $10.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 2,477 | 6,465 | 753 | $16K |
| Losartan Potassium Generic | 2,144 | 5,772 | 658 | $15K |
| Amlodipine Besylate Generic | 1,689 | 4,460 | 526 | $6,204 |
| Pantoprazole Sodium Generic | 1,531 | 1,722 | 459 | $5,142 |
| Montelukast Sodium Generic | 1,516 | 1,721 | 384 | $5,322 |
| Gabapentin Generic | 1,291 | 1,488 | 331 | $5,841 |
| Famotidine Generic | 1,268 | 1,526 | 287 | $4,462 |
| Diclofenac Sodium Generic | 1,079 | 1,132 | 319 | $434K |
| Tamsulosin Hcl Generic | 1,051 | 2,539 | 311 | $9,436 |
| Farxiga Dapagliflozin Propanediol | 1,002 | 1,844 | 257 | $1.0M |
| Metformin Hcl Er Metformin Hcl | 993 | 2,563 | 295 | $5,798 |
| Vascepa Icosapent Ethyl | 980 | 1,471 | 198 | $491K |
| Triamcinolone Acetonide Generic | 907 | 939 | 305 | $5,792 |
| Fluticasone Propionate Generic | 892 | 965 | 229 | $7,330 |
| Metformin Hcl Generic | 701 | 1,682 | 192 | $4,209 |
Brand drugs: 12,188 claims; generic drugs: 37,832 claims; opioid claims: 1,317.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael M Dao $11K ($11K in general payments such as food, travel and fees) from 54 companies. The largest payer was Agios Pharmaceuticals, Inc. with $3,107.
| Company | Payments | Amount |
|---|---|---|
| Agios Pharmaceuticals, Inc. AGIO | 4 | $3,107 |
| Amgen Inc. AMGN | 47 | $897 |
| AstraZeneca Pharmaceuticals LP AZN | 13 | $724 |
| Abbvie Inc. ABBV | 25 | $640 |
| Aimmune Therapeutics, Inc. | 23 | $429 |
| Ardelyx, Inc. ARDX | 19 | $391 |
| Axsome Therapeutics, Inc. AXSM | 7 | $370 |
| Phathom Pharmaceuticals, Inc. PHAT | 10 | $315 |
| Novartis Pharmaceuticals Corporation NVS | 21 | $280 |
| Viatris Specialty LLC | 7 | $266 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.